Iovance Biotherapeutics (IOVA) Peer Comparison

$10.99

$-0.01 (-0.09%)

As on 28-Sep-2026 16:24EDT

Market cap

$4,983 Mln

Revenue (TTM)

$325 Mln

P/E Ratio

--

P/B Ratio

6.4

Div. Yield

0 %

Edit

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	4,983	17,274	14,841	14,411	12,927
Revenue ($ Mln)	325	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-289.52	491.50	755.85	860.62	413.60
Net Margin (%)	-89.09	17.67	71.69	35.33	24.86
RoE (%)	-40.36	110.09	--	42.98	430.03
Price to Earnings	--	36.40	17.63	18.29	33.40
Price-To-Book	6.38	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	324.97	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	-52.97	1,982.07	103.47	85.67	363.07
Gross Profit	256.22	760.62	588.53	2,236.43	1,091.18
Operating Expenses	679.25	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	-301.31	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-293.78	598.92	101.11	1,035.47	583.34
Provision for Tax	-4.26	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-289.52	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	736.05	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	72.64	187.89	384.48	288.55	2,089.43
Current Liabilities	106.85	1,435.43	464.70	361.93	344.44
Total Liabilities	913.17	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	451.27	1,006.90	895.24	1,243.41	1,644.38
Current Assets	464.26	1,050.29	1,389.84	1,250.82	933.02
Total Assets	913.17	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	46.00	120.10	449.89	165.93	2,146.65
Net Current Assets	357.41	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-302.41	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	47.50	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	300.77	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-51.59	53.56	-30.01	32.82	15.61
ROE (%)	-40.36	110.09	163.18	42.98	430.03
ROA (%)	-28.12	15.64	31.68	29.32	16.19
EBIT Margin (%)	-90.40	21.13	5.73	31.04	36.28
Net Margin (%)	-89.09	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	34.55	24.67	114.85	9.23	41.15
EBIT Growth (%)	25.39	18.70	136.39	-3.99	-14.99
Net Profit Growth (%)	25.75	17.50	378.76	42.89	-25.78
EPS Growth (%)	41.20	26.84	353.27	50.42	-23.48
Book Value Growth (%)	-21.70	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-2.84	36.06	-59.76	15.79	24.99
Price / Book Value	1.59	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.42	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.00	0.27	0.00	13.50
Short term debt to equity ratio	0.00	0.00	0.05	0.00	1.46
Current Ratio	4.35	0.73	2.99	3.46	2.71
Quick Ratio	3.82	0.73	2.32	3.38	2.31
Interest Coverage	--	--	1.62	--	29.73

Operating Efficiency Ratios

	Iovance Biotherapeutics (IOVA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	31.42	15.88	21.25	13.74	27.40
Asset Turnover	0.32	0.89	0.44	0.83	0.65
Receivable days	105.20	50.42	85.52	43.48	98.04
Inventory Days	2,586.68	--	1,056.70	96.17	190.34
Payable days	1,244.94	6.26	331.01	147.97	18.62
Cash Conversion Cycle	1,446.94	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly